Clinical Trial News and Research

RSS

New AI system can help identify novel therapeutic targets implicated in various diseases

Insilico Medicine is pleased to announce that it has entered into a collaboration with Teva Branded Pharmaceutical Products R&D, Inc. to utilize Insilico's generative machine learning technology and proprietary PandaOmics Drug Discovery Platform, which aims at identifying novel therapeutic targets implicated in a variety of diseases.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

Researchers analyze how breast implant surfaces influence immune response

Rice University bioengineers collaborated on a six-year study that systematically analyzed how the surface architecture of breast implants influences the development of adverse effects, including an unusual type of lymphoma.

21 Jun 2021

Investigational Alzheimer's drug reduces molecular markers of the disease

An investigational Alzheimer's drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU).

21 Jun 2021

New breakthrough could lead to a cure for common childhood cancer

Scientists studying a common childhood cancer have made a major breakthrough which could lead to a cure for some youngsters who would not have survived the condition.

21 Jun 2021

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

Researchers from the German Center for Infection Research at Charité - Universitätsmedizin Berlin and the University of Bonn have examined the way in which SARS-CoV-2 reprograms the metabolism of the host cell in order to gain an overall advantage.

21 Jun 2021

Zinc inhibits SARS-CoV-2’s main protease in vitro

Zinc has antiviral properties. However, the detailed kinetics and the mechanism of zinc in the inhibition of viruses, particularly SARS-CoV-2 – the causative virus of COVID-19 – is unclear. To probe the role of zinc as an anti-SARS-CoV-2 agent at the structural and molecular level, researchers in India studied the binding kinetics and the inhibition mechanism of zinc with SARS-CoV-2’s viral proteins.

21 Jun 2021

Researchers describe a new science-based intervention for hiccups

Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and colleagues worldwide describe a new science-based intervention for hiccups in a research letter published June 18 in the journal JAMA Network Open.

21 Jun 2021

Study uncovers new mechanisms underlying lineage plasticity

Cancer cells have an uncanny ability to evolve and adapt to overcome the treatments used against them. While patient survival has been extended by modern drugs that block the production or action of male hormones that fuel prostate cancer -- androgen receptor inhibitors such as enzalutamide, apalutamide, darolutamide, and abiraterone -- eventually these drugs stop working.

21 Jun 2021

New artificial heart can adjust the changing needs of patients treated for end-stage heart failure

An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus.

18 Jun 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.

18 Jun 2021

Genetically engineering NK cells can destroy tumor-regenerating glioblastoma stem cells

Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted by natural killer (NK) cells, they are able to evade immune attack by releasing the TFG-β signaling protein, which blocks NK cell activity.

17 Jun 2021

Clinical trial shows induced hypothermia after cardiac arrest does not improve survival

Since 2005, the guidelines for the care of unconscious cardiac arrest patients have been to cool the body temperature down to 33 degrees Celsius. A large, randomized clinical trial led by Lund University and Region Skåne in Sweden has shown that this treatment does not improve survival. The study is published in the New England Journal of Medicine.

16 Jun 2021

New computational topology strategy to identify existing medicines for treating COVID-19

Researchers from the ESI International Chair of the CEU Cardenal Herrera University (CEU UCH) and ESI Group have just published in scientific journal Pharmaceutics a new computational topology strategy to identify existing medicines that could be applied to treat COVID-19 without waiting for the research and clinical trial phases required to develop a new medicine.

16 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

Studies shed new light on disease processes in tuberculosis

Two new studies have cast unprecedented light on disease processes in tuberculosis, identifying key genetic changes that cause damage in the lungs and a drug treatment that could speed up recovery.

16 Jun 2021

Clinical Trial News and Research

New AI system can help identify novel therapeutic targets implicated in various diseases

New study enrolls young adults to evaluate SARS-CoV-2 infection

Researchers analyze how breast implant surfaces influence immune response

Investigational Alzheimer's drug reduces molecular markers of the disease

New breakthrough could lead to a cure for common childhood cancer

Researchers identify four substances that inhibit SARS-CoV-2 replication in cells

Zinc inhibits SARS-CoV-2’s main protease in vitro

Researchers describe a new science-based intervention for hiccups

Study uncovers new mechanisms underlying lineage plasticity

New artificial heart can adjust the changing needs of patients treated for end-stage heart failure

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

Convalescent plasma can improve chances of survival among blood cancer patients with COVID-19

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding immune oncology drug to chemotherapy improves response in subset of breast cancer patients

Genetically engineering NK cells can destroy tumor-regenerating glioblastoma stem cells

Clinical trial shows induced hypothermia after cardiac arrest does not improve survival

New computational topology strategy to identify existing medicines for treating COVID-19

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

Studies shed new light on disease processes in tuberculosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

New horizons in drug discovery: High-throughput & target-to-therapy advances

A practical guide to lipid nanoparticle formulation and resizing

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance